Pipeline
Proof of concept to be generated by 5 clinical trials
Indications Protocol Location Development Stage Preclinical Phase 1 Phase 2 Phase 3 Brain Metastases NANORAD 2 100 patients randomized NANOBRAINMETS Glioblastoma NANO-GBM Pancreatic/ NANOSMART Cervical Cancer NANOCOL
CHU Grenoble-AlpesRecruiting Phase 2
Dr. Aizer at Dana-Farber/Harvard Cancer Center
134 patients randomizedRecruiting Phase 2
Centre Jean Perrin
66 patients randomizedRecruiting Phase 1
Non Small Cell
Lung Cancer
Dr. Leeman at Dana-Farber/Harvard Cancer Center
100 patients randomizedRecruiting Phase 1
Institut Gustave Roussy
12 patientsRecruitment completed
ODD: Orphan Drug Designation obtained from both the FDA and the EMA

: Phase 2 protocol approved